Pan-cancer panel aligns with pharma industry targets

Global liquid biopsy company ANGLE, has granted genomics and molecular diagnostics company, NuProbe USA, Inc. use of its proprietary pan-cancer next generation sequencing (NGS) panel.

Under the agreement, NuProbe has the option for an exclusive global license to the panel outside of China for the analysis of circulating tumour cell (CTC) solutions CTCs and the dual analysis of CTCs and ctDNA. NuProbe will transfer manufacture of the NGS panel to a larger-scale site and ANGLE will undertake internal validation of the initial batches.

Validated on the Illumina sequencer, the panel enables specific detection of over 6,500 DNA mutations in 61 clinically relevant genes, including those with matched targeted therapies currently selected using assays which use tumour tissue or circulating tumour DNA (ctDNA) and aligns with many key drug targets under development by large pharma.

NuProbe Chief Executive Officer, Yingshuang Chai, commented: “We are excited to enter into an agreement with ANGLE plc, a world leader in the harvest of CTCs from blood for analysis. NuProbe’s NGS panel is a low-cost, ultra-sensitive pan-cancer NGS panel that can accurately detect mutations and has demonstrated robust performance in both CTC and ctDNA sample types. By combining CTC and ctDNA detection, this collaboration will help drive the development of personalised treatment options for cancer patients. We look forward to the development of a strong partnership with ANGLE in the future.”

ANGLE Chief Executive Officer, Andrew Newland, commented: “The Company’s marker-independent Parsortix system has been exemplified in 24 cancer types representing 90% of all solid tumour cases. As such we are strongly positioned to leverage a pan-cancer gene panel across 61 oncogenes and thousands of mutations. The Company believes that this agreement will enable us to combine the leading CTC harvesting solution with an optimised DNA sequencing panel for analysis of CTCs and dual analysis of CTCs and ctDNA.”

More information online